On this page
Back to topKestra Medical Technologies KMTS
Kestra Medical Technologies listed on Nasdaq on 6 Mar 2025 and is not in the S&P 500. It is worth $1.6 billion. Its board has 8 directors, 6 of them independent. 3 other officers are on file. At 30 Jun 2026, Bain Capital Investors was its largest institutional holder, with 43.1% of the company.
- CEO
- Brian Daniel Webster
- Chair
- Jeffrey Lawrence Schwartz
- Listed
- 6 Mar 2025 on Nasdaq
- Headquarters
- Kirkland, WA
- Market cap
- $1.6B
- 19 Nov 2026 close
- Price to sales
- 16.7
- Market cap over revenue
Financials
Financial history
Twelve months to 31 Jul 2026, from Kestra Medical Technologies' quarterly filings.
Quarters since Jul 2024
- Revenue
- $107M
- Up 61% on the year before
- Net income
- $-150M
- -140.4% of revenue
- Free cash flow
- $-123M
- Operating cash flow less capital spending
- P/E
- -
- No profit over the last four quarters
Quarterly results
Each quarter's revenue, net income and free cash flow.
Jul 2024 to Jul 2026
| Quarter | Revenue | Net income |
|---|---|---|
| Jul 2026 | $31M | $-44M |
| Apr 2026 | $29M | $-39M |
| Jan 2026 | $25M | $-34M |
| Oct 2025 | $23M | $-33M |
| Jul 2025 | $19M | $-26M |
| Apr 2025 | $17M | $-52M |
| Jan 2025 | $15M | $-22M |
| Oct 2024 | $15M | $-20M |
| Jul 2024 | $13M | $-20M |
Kestra Medical Technologies' market cap since March 2025
Marked weeks are changes in the share count, such as a merger, not market moves.
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $1.7B |
| 26 Dec 2025 | $1.6B |
Download Kestra Medical Technologies' data as JSON, with the weekly market caps in billions of dollars from 7 Mar 2025.
Board and leadership
Board and officers
Board from the proxy filed 28 Jul 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (8) | |||||
| Jeffrey Lawrence SchwartzChairIndependent · since 2023 · Compensation, Nominating and Corporate Governance (chair)Partner and Chief Operating Officer for Global Private Equity, Bain Capital Private Equity, LP | |||||
| Brian Daniel WebsterPresident and Chief Executive OfficerNot independent · since 2021 | |||||
| Raymond W. CohenDirectorIndependent · since 2025 · Audit, Compensation (chair)Operating Partner, Star51 Capital and Venture Partner, Andera Partners and Sherpa Capital PartnersOther boards: RxSight | |||||
| Conor HanleyDirectorIndependent · since 2025 · AuditChief Executive Officer, Foundry Innovation & Research 1, Ltd. (FIRE1) | |||||
| Elizabeth KwoDirectorIndependent · since 2025 · Nominating and Corporate GovernancePresident, Vanna Health, Inc.Other boards: Walmart de México y Centroamérica | |||||
| Mary Kay LadoneDirectorIndependent · since 2025 · Audit (chair), Nominating and Corporate GovernanceDirectorOther boards: Novanta, Bioventus and Inogen | |||||
| Kevin C. ReillyDirectorIndependent · since 2025 · CompensationManaging Director, Head of Medtech, Ally Bridge Group | |||||
| Traci S. UmbergerGeneral Counsel and Chief Adminstrative OfficerNot independent · since 2021 | |||||
| Officers (3) | |||||
| Vaseem MahboobChief Financial OfficerLast filed 11 Aug 2026 | |||||
| Alfred J. Ford Jr.Chief Commercial OfficerLast filed 6 Aug 2026 | |||||
| Timothy P. MoranChief Business OfficerLast filed 3 Aug 2026 | |||||
Owners and trading
Largest institutional holders
Each fund group's share of Kestra Medical Technologies. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers sold $16.0 million of stock in 44 sales and bought $199,800 in 1 purchase in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 18 Nov 2026Sale | Brian Daniel WebsterPresident and Chief Executive Officer | $427K |
| 3 Nov 2026Sale | Timothy P. MoranChief Business Officer | $94K |
| 29 Oct 2026Sale | Vaseem MahboobChief Financial Officer | $147K |
| 28 Oct 2026Sale | Vaseem MahboobChief Financial Officer | $1.2M |
| 27 Oct 2026Sale | Vaseem MahboobChief Financial Officer | $1.0M |
| 27 Oct 2026Sale | Traci S. UmbergerGeneral Counsel and Chief Adminstrative Officer | $901K |
| 21 Oct 2026Sale | Traci S. UmbergerGeneral Counsel and Chief Adminstrative Officer | $2.7M |
| 20 Oct 2026Sale | Brian Daniel WebsterPresident and Chief Executive Officer | $443K |
| 30 Sep 2026Sale | Raymond W. CohenDirector | $98K |
| 21 Sep 2026Sale | Elizabeth KwoDirector | $97K |
Showing 10 of 45 trades
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
0 departures and 1 appointment of directors and officers and 5 large insider sales in the last two years.
Insider sales of $1 million or more, and the largest tenth of Kestra Medical Technologies' insider sales.
Events, newest first
- 28 Oct 2026 Vaseem Mahboob sold $1.2MChief Financial Officer
- 27 Oct 2026 Vaseem Mahboob sold $1.0MChief Financial Officer
- 27 Oct 2026 Traci S. Umberger sold $901KGeneral Counsel and Chief Adminstrative Officer
- 21 Oct 2026 Traci S. Umberger sold $2.7MGeneral Counsel and Chief Adminstrative Officer
- 4 Aug 2026 Brian Daniel Webster sold $1.3MPresident and Chief Executive Officer
- 4 Jun 2025 Conor Hanley appointedMember of the Board
| Date | Event | Filing |
|---|---|---|
| 28 Oct 2026 | Vaseem Mahboob sold $1.2MChief Financial Officer | Form 4 |
| 27 Oct 2026 | Vaseem Mahboob sold $1.0MChief Financial Officer | Form 4 |
| 27 Oct 2026 | Traci S. Umberger sold $901KGeneral Counsel and Chief Adminstrative Officer | Form 4 |
| 21 Oct 2026 | Traci S. Umberger sold $2.7MGeneral Counsel and Chief Adminstrative Officer | Form 4 |
| 4 Aug 2026 | Brian Daniel Webster sold $1.3MPresident and Chief Executive Officer | Form 4 |
| 4 Jun 2025 | Conor Hanley appointedMember of the Board | 8-K |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.